64 related articles for article (PubMed ID: 21908103)
21. Role of gastrin-releasing peptide and neuromedin B in anxiety and fear-related behavior.
Bédard T; Mountney C; Kent P; Anisman H; Merali Z
Behav Brain Res; 2007 Apr; 179(1):133-40. PubMed ID: 17335915
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075.
Chen CP; Hu CB; Yeh KC; Song JS; Yeh TK; Tung FF; Hwang LL; Tseng HY; Huang YC; Shy HS; Hsieh SH; Shen CC; Wang HS; Hsieh HP; Liou JP; Chao YS; Chen CT
Anticancer Res; 2010 Jul; 30(7):2813-22. PubMed ID: 20683017
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
Orbuch M; Taylor JE; Coy DH; Mrozinski JE; Mantey SA; Battey JF; Moreau JP; Jensen RT
Mol Pharmacol; 1993 Oct; 44(4):841-50. PubMed ID: 7901752
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
Bandyopadhyay A; López-Casillas F; Malik SN; Montiel JL; Mendoza V; Yang J; Sun LZ
Cancer Res; 2002 Aug; 62(16):4690-5. PubMed ID: 12183427
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
26. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Reimer CL; Agata N; Tammam JG; Bamberg M; Dickerson WM; Kamphaus GD; Rook SL; Milhollen M; Fram R; Kalluri R; Kufe D; Kharbanda S
Cancer Res; 2002 Feb; 62(3):789-95. PubMed ID: 11830534
[TBL] [Abstract][Full Text] [Related]
27. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.
Lamszus K; Jin L; Fuchs A; Shi E; Chowdhury S; Yao Y; Polverini PJ; Laterra J; Goldberg ID; Rosen EM
Lab Invest; 1997 Mar; 76(3):339-53. PubMed ID: 9121117
[TBL] [Abstract][Full Text] [Related]
28. 3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells.
Jin Y; Zou X; Feng X
Anticancer Drugs; 2010 Oct; 21(9):814-22. PubMed ID: 20724916
[TBL] [Abstract][Full Text] [Related]
29. Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis.
Wang Z; Loo WT; Wang N; Chow LW; Wang D; Han F; Zheng X; Chen JP
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S79-89. PubMed ID: 22316502
[TBL] [Abstract][Full Text] [Related]
30. Neuromedin B stimulates proliferation of mouse chondrogenic cell line ATDC5.
Saito H; Ikeda R; Inoue K; Nagata S; Kitamura K; Minamino N; Kangawa K; Miyata A
Peptides; 2012 Aug; 36(2):299-302. PubMed ID: 22652580
[TBL] [Abstract][Full Text] [Related]
31. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells.
Moody TW; Leyton J; Garcia-Marin L; Jensen RT
Eur J Pharmacol; 2003 Aug; 474(1):21-9. PubMed ID: 12909192
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic drugs increase xenograft aggressiveness.
Cancer Discov; 2012 Mar; 2(3):OF3. PubMed ID: 22586000
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368.
Tokita K; Hocart SJ; Katsuno T; Mantey SA; Coy DH; Jensen RT
J Biol Chem; 2001 Jan; 276(1):495-504. PubMed ID: 11013243
[TBL] [Abstract][Full Text] [Related]
34. Stress-induced impairment of inhibitory avoidance learning in female neuromedin B receptor-deficient mice.
Yamada K; Santo-Yamada Y; Wada K
Physiol Behav; 2003 Feb; 78(2):303-9. PubMed ID: 12576129
[TBL] [Abstract][Full Text] [Related]
35. Restraint stress impaired maternal behavior in female mice lacking the neuromedin B receptor (NMB-R) gene.
Yamada K; Santo-Yamada Y; Wada K
Neurosci Lett; 2002 Sep; 330(2):163-6. PubMed ID: 12231437
[TBL] [Abstract][Full Text] [Related]
36. Effect of NMB-regulated ERK1/2 and p65 signaling pathway on proliferation and apoptosis of cervical cancer.
Zeng R; Xiong X
Pathol Res Pract; 2022 Oct; 238():154104. PubMed ID: 36095918
[TBL] [Abstract][Full Text] [Related]
37. Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells.
Park HJ; Kim MK; Choi KS; Jeong JW; Bae SK; Kim HJ; Bae MK
Int J Oncol; 2016 Sep; 49(3):934-42. PubMed ID: 27571778
[TBL] [Abstract][Full Text] [Related]
38. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
39. New Insights into the Stereochemical Requirements of the Bombesin BB1 Receptor Antagonists Binding.
Rasaeifar B; Gomez-Gutierrez P; Perez JJ
Pharmaceuticals (Basel); 2020 Aug; 13(8):. PubMed ID: 32824403
[TBL] [Abstract][Full Text] [Related]
40. Neuromedin B receptor disruption impairs adipogenesis in mice and 3T3-L1 cells.
de Paula GSM; Wilieman M; Silva KR; Baptista LS; Boudina S; de Souza LL; Bento-Bernardes T; Asensi KD; Goldenberg RCDS; Pazos-Moura CC
J Mol Endocrinol; 2019 Jul; 63(1):93-102. PubMed ID: 31067509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
